International Psoriasis Symposium
ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
Amgen (NASDAQ: AMGN), the world’s largest biotechnology company, and Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), announce that patients in a second phase 3 clinical study assessing the efficacy and tolerability of ENBREL (etanercept) in the treatment of moderate to severe plaque psoriasis experienced significant and rapid improvement in their symptoms. Psoriasis affects nearly 7 million Americans, one million of whom have moderate to severe plaque psoriasis.Contact: Rebecca Hamm, Amgen
805-447-3872
Porter NovelliEuropean League Against Rheumatism
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announce that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The painful, chronic and progressive inflammatory disease affects about 350,000 people in the United States.Contact: Rebecca Hamm, Amgen
805-447-3872
Porter NovelliEuropean League Against Rheumatism (EULAR) Annual Congress of Rheumatology
Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announce that patients receiving ENBREL(R) (etanercept) 50 mg once weekly for the treatment of active rheumatoid arthritis (RA) in a new study experienced significant improvements in function and pain comparable to those receiving the currently approved dose (25 mg twice weekly), and significantly better than those receiving placebo. RA affects more than two million Americans.Contact: Rebecca Hamm, Amgen
805-447-3872
Porter NovelliEuropean League Against Rheumatism
ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced ENBREL (R) (etanercept) in combination with methotrexate or alone had a more significant impact on the progression of structural damage in rheumatoid arthritis (RA) patients versus methotrexate alone, according to one-year results of TEMPO, (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes). RA affects more than two million Americans.Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
Some information from my former company about a drug that I did some work on. Great news for patients. I wish it was Immunex that was giving this news and not Amgen but it is something that will help a lot of patients.
A Man With A Ph.D. 